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Abstract: De novo drug design is a computational approach that generates novel molecular structures
from atomic building blocks with no a priori relationships. Conventional methods include structure-
based and ligand-based design, which depend on the properties of the active site of a biological target
or its known active binders, respectively. Artificial intelligence, including ma-chine learning, is an
emerging field that has positively impacted the drug discovery process. Deep reinforcement learning
is a subdivision of machine learning that combines artificial neural networks with reinforcement-
learning architectures. This method has successfully been em-ployed to develop novel de novo
drug design approaches using a variety of artificial networks including recurrent neural networks,
convolutional neural networks, generative adversarial networks, and autoencoders. This review
article summarizes advances in de novo drug design, from conventional growth algorithms to
advanced machine-learning methodologies and high-lights hot topics for further development.
Keywords: de novo drug design; artificial intelligence; machine learning; deep reinforcement
learning; artificial neural networks; recurrent neural networks; convolutional neural networks;
generative adversarial networks; autoencoders
1. Introduction
The development of a chemical entity and its testing, evaluation, and authorization to
become a marketed drug is a laborious and expensive process that is prone to failure [1].
Indeed, it is estimated that just 5 in 5000 drug candidates make it through preclinical
testing to human testing and just one of those tested in humans reaches the market [2].
The discovery of novel chemical entities with the desired biological activity is crucial to
keep the discovery pipeline going [3]. Thus, the design of novel molecular structures for
synthesis and in vitro testing is vital for the development of novel therapeutics for future
patients. Advances in high-throughput screening of commercial or in-house compound
libraries have significantly enhanced the discovery and development of small-molecule
drug candidates [4]. Despite the progress that has been made in recent decades, it is
well-known that only a small fraction of the chemical space has been sampled in the search
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for novel drug candidates. Therefore, medicinal and organic chemists face a great challenge
in terms of selecting, designing, and synthesizing novel molecular structures suitable for
entry into the drug discovery and development pipeline.
Computer-aided drug design methods (CADD) have become a powerful tool in
the process of drug discovery and development [5]. These methods include structure-
based design such as molecular docking and dynamics, and ligand-based design such as
quantitative structure–activity relationships (QSAR) and pharmacophore modeling. In
addition, the increasing number of X-ray, NMR, and electron microscopy structures of
biological targets, along with state-of-the-art, fast, and inexpensive hardware, have led to
the development of more accurate computational methods that accelerated the discovery
of novel chemical entities. However, the complexity of signaling pathways that represent
the underlying biology of human diseases, and the uncertainty related to new therapeutics,
require the development of more rigorous methods to explore the vast chemical space and
facilitate the identification of novel molecular structures to be synthesized [6].
De novo drug design (DNDD) refers to the design of novel chemical entities that fit a
set of constraints using computational growth algorithms [7]. The word “de novo” means
“from the beginning”, indicating that, with this method, one can generate novel molecular
entities without a starting template [8]. The advantages of de novo drug design include the
exploration of a broader chemical space, design of compounds that constitute novel intel-
lectual property, the potential for novel and improved therapies, and the development of
drug candidates in a cost- and time-efficient manner. The major challenge faced in de novo
drug design is the synthetic accessibility of the generated molecular structures [9]. In this
paper, advances in de novo drug design are discussed, spanning from conventional growth
to machine learning approaches. Briefly, conventional de novo drug design methodologies,
including structure-based and ligand-based design using evolutionary algorithms, are
presented. Design constraints can include, but are not limited to, any desired property or
chemical characteristic, for example: predefined solubility range, toxicity below a thresh-
old, and specific chemical groups included in the structure. Finally, machine-learning
approaches such as deep reinforcement learning and its application in the development of
novel de novo drug design methods are summarized. Future directions for this important
field, including integration with toxicogenomics and opportunities in vaccine development,
are presented as the next frontiers for machine-learning-enabled de novo drug design.
2. De Novo Drug Design Methodology
De novo drug design is a methodology that creates novel chemical entities based only
on the information regarding a biological target (receptor) or its known active binders
(ligands found to possess good binding or inhibitory activity against the receptor) [10–14].
The major components of de novo drug design include a description of the receptor
active site or ligand pharmacophore modeling, construction of the molecules (sampling),
and evaluation of the generated molecules. Two major de novo drug-design approaches
are available including structure-based and ligand-based design (Figure 1). The three-
dimensional structures of a receptor are generally available through X-ray crystallography,
NMR, or electron microscopy [15,16]. When the structure of the receptor is unknown,
homology modeling can be employed to acquire a suitable structure for de novo drug
design [17]. However, the quality of a homology model depends on the quality of the
template structure and sequence similarity. The Ligand-based approach is generally used
when no structural data for the biological target are available, but instead one or more
active binders are known [3].
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Figure 1. Schematic representation of the de novo drug-design methodology.
2.1. Structure-Based De Novo Drug Design
Receptor-based de novo drug design begins with defining the active site of the receptor.
Since the molecular shape, physical, and chemical properties of the active site are important
for tight and specific binding of a ligand, the active site is analyzed to determine the shape
constraints and the non-covalent interactions for a ligand [9]. Receptor–ligand non-covalent
interactions consist of hydrogen-bonds, electrostatic, and hydrophobic interactions and are
used to generate interaction sites for a ligand. These sites play a significant role in reducing
the high number of generated structures, thus increasing selectivity. There are several
methods used to define interaction sites for the active site of the receptor. An example is
HSITE, a rule-based method which considers only hydrogen-bond donors and acceptors
generating a map of hydrogen-bonding regions [18]. LUDI and PRO_LIGAND are other
ruled-based methods that also consider hydrophobic interaction sites [19–21]. HIPPO is a
ruled-based method that considers the interaction sites of covalent bonds and metal ion
bonds [22]. Other methods include grid-based approaches, in which a grid of points is
generated in the active site of the receptor, and interaction energies for hydrogen-bonding
or hydrophobic interactions are calculated using probe atoms or fragments at each grid
point [23–25]. Multiple-copy simultaneous search (MCSS) is a method that randomly
docks functional groups in the active site to determine energetically favorable positions
and orientations [26,27]. The functional groups are then minimized using a force-field,
and groups are discarded if the interaction energy between them and the active site is
not favorable based on a threshold value. The evaluation of the candidate structures is
important in de novo drug design and it is generally performed by calculating the free
binding energy of the candidate molecule with the binding site of the receptor using scoring
functions. The main scoring functions used to evaluate the generated structures include
force fields, empirical scoring functions, and knowledge-based scoring functions [28–32].
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2.2. Ligand-Based De Novo Drug Design
When the three-dimensional structure of a biological target is absent, known active
binders offer an alternative strategy for de novo drug design [3]. Such data are available
in the literature from screening efforts or structure–activity relationship studies [33]. Ac-
tive binders can also be found in databases such as ChEMBL, which contains bioactive
molecules with drug-like properties [34]. This method is often employed to design novel
candidate structures for biological targets for which obtaining a crystal structure is chal-
lenging [35]. From one or more known active binders, a ligand pharmacophore model is
established and used to design novel structures. In particular, the ligand pharmacophore
model can be utilized either to create a pseudo-receptor or to directly perform similarity
design [21]. It is worth mentioning that the quality of the pharmacophore model plays
a significant role in ligand-based de novo drug design and it depends on the structural
diversity of the known binders. The possibility of different binding modes requires the
assumption of a common binding mode to build the pharmacophore model. A quantitative
structure–activity relationship model can be used in parallel to evaluate the quality of the
pharmacophore model [36]. Examples of ligand-based de novo drug design tools include
TOPAS [37], SYNOPSIS [38], and DOGS [39].
2.3. Sampling Methods in De Novo Drug Design
Sampling of the candidate structures can be achieved by two methods, namely atom-
based and fragment-based approaches [8,9]. In atom-based sampling, an initial atom is
randomly placed in the active site and used as a seed to construct the rest of the molecule. In
every stage, a variety of atoms and hybridization states of each atom are explored. As a re-
sult, the chemical space covered by this method is vast and the generated structures need to
be narrowed down. This is typically achieved by filtering the structures based on chemical
accessibility. Atom-based sampling has the advantage of a higher exploration of the chem-
ical space, and thus a greater number and variety of structures are generated. However,
the high number of generated structures makes it difficult to identify suitable compounds
for synthesis and experimental testing. LEGEND is an example of an atom-based de novo
drug-design algorithm [24]. Fragment-based sampling is the preferred method in de novo
drug design because the structures are generated as fragment assemblies, which narrows
the chemical search space, maintains good diversity, and generates candidate compounds
with chemical accessibility and optimal adsorption, distribution, metabolism, excretion
and toxicity (ADMET) properties [8]. This method requires a database that contains frag-
ments and linkers, which are obtained either virtually or experimentally [3]. A fragment is
docked in the active site and is utilized as a seed to build the rest of the molecule [40–42].
Examples of algorithms that employ fragment-based design as a sampling method include
LUDI [43], PRO_LIGAND [20], SPROUT [44], and CONCERTS [29]. It is worth mentioning
that drug properties such as ADMET can be implemented in de novo drug design using
secondary target constraints [9]. For example, structures with drug-like properties such as
oral bioavailability can be obtained by filtering the proposed structures using Lipinski’s
rule of five or other in silico predictive models [45–47].
3. Evolutionary Algorithms in De Novo Drug Design
Evolutionary algorithms have been extensively used in de novo drug design [8]. These
algorithms are subdivided into genetic algorithms, genetic programming, evolutionary
programming, and evolutionary strategies, which are based on population optimization
using mechanisms inspired by biological evolution, such as reproduction, mutation, re-
combination (crossover), and selection [48,49]. In the case of drug design, a population
of structures or conformations is created, and each member of the population is encoded
by a randomly generated chromosome. The cycle begins with the generation of a “par-
ent” population from a randomly (stochastically) created initial population (Figure 2).
Each parent undergoes a random transformation using genetic operators to generate a
population of new structures, called “children”. The two principal operators used are
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mutation and crossover. Mutation generates new populations by introducing new infor-
mation, while crossover uses this information to create new individual populations of the
candidate structures. A fitness function is then employed to evaluate the binding score of
each “child” structure. Based on the score, a new generation of parents is selected from
the combined population of the initial “parents” and “children”. This new population of
“parents” is used in the next cycle. This cycle is repeated until the termination criterion is
fulfilled [50–52]. The main evolutionary techniques used in de novo drug design include
genetic algorithms, evolutionary strategies, and evolutionary graphs [8]. Examples of de
novo drug-design applications using genetic algorithms include LigBuilder [25], LEA [53],
ADAPT [54], PEP [55], SYNOPSIS [38], LEA3D [56], GANDI [40] and ML GAN [57]. De
novo drug-design tools utilizing evolutionary strategies are TOPAS [37], Flux(1) [58], and
FLUX [59]. Finally, examples of de novo drug-design applications employing evolutionary
graphs are MEGA [60] and EvoMD [61].
Figure 2. Schematic representation of the evolutionary algorithmic cycle in de novo drug design.
4. Artificial Intelligence in De Novo Drug Design
Artificial intelligence (AI) is a scientific field that exploits the ability of machines to
mimic human cognitive functions such as learning and problem solving (Figure 3) [62–65].
Machine learning (ML) is a subdivision of AI that enables machines to learn from data using
statistical methods and to make predictions [66,67]. ML methods have been employed to
predict outcomes related to drug discovery [68]. Deep learning (DL) is a subdivision of ML
which makes the computation of multilayer neural networks feasible [69]. The increased
volumes of data available, combined with continuous increasing computer power, gave rise
to DL methods such as recurrent neural networks (RNN), convolutional neural networks
(CNN), generative adversarial networks (GAN), and autoencoders (AE). Reinforcement
learning (RL) is another subdivision of machine learning, based on rewarding desired
behaviors and/or punishing undesired ones [70]. Deep reinforcement learning (DRL) is a
combination of artificial neural networks with reinforcement learning architectures, and
has recently been employed in de novo drug design [71,72]. Such methods are expected to
revolutionize the field of drug discovery since they are remarkably successful in other fields
including recognition of speech [73], formal languages [74], video representations [75],
music [76], and more.
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Figure 3. Artificial intelligence methods such as machine, deep, and reinforcement learning have been successfully employed
in de novo drug design.
Deep Reinforcement Learning (DRL) in De Novo Drug Design
Among the range of AI subdivisions, DL has been very popular in mimicking human
abilities of image recognition and natural language processing [77]. In addition, DL has
been employed for the development of analysis approaches in data-driven fields such as
biomedicine and healthcare [78,79]. In drug discovery, DL was initially employed for the
development of QSAR to predict properties such as affinity, toxicity, etc. [80,81]. Advances
in drug discovery DL methods led to the development of fully connected neural networks
using molecular descriptors calculated directly from molecular structures [82]. De novo
drug design using DRL, which combines artificial neural networks with reinforcement
learning, is a breakthrough in the field of drug discovery [72,83]. DRL approaches in
de novo drug design typically consist of a generative model (generator) and a de novo
drug-design agent that uses reinforcement learning (Figure 4). For the generative model, a
multilayer artificial neural network is used. Depending on the type of artificial network,
the input layer might consist of SMILES or graphs of molecules [84]. SMILES represents
a molecule as a sequence of characters corresponding to atoms and special characters
denoting connectivity [85]. The neural network is then trained using tokens of pre-existing
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data such as known bioactive molecules for a specific biological target. Construction of
output structures is a result of iterative learning and decision-making steps [83]. At each
step, the model determines the optimal token from the vocabulary based on the generated
sequence of previous steps. The de novo drug design agent is part of the reinforcement
framework, and it could be conceptualized as a virtual robot that interacts with molecules
and modifies them to improve their properties. The actions of the agent are controlled by
the artificial neural network, also called the generator.
Figure 4. Deep reinforcement learning consists of a generator which is usually an artificial neural network and a de novo
drug-design agent that uses reinforcement learning to make decisions for the generation of novel molecular structures.
5. Examples of DRL in De Novo Drug Design
5.1. Recurrent Neural Networks (RNN)
A recurrent neural network (RNN) is an artificial neural network architecture that
employs cyclic connections between neurons [86,87]. These connections enable an RNN to
have an inner representation of the current state, which enables it to remember information
from previous steps in a sequence. Because of that, an RNN is suitable for the analysis
of sequential data such as text or molecules represented as a sequence of characters like
SMILES. RNN works sequentially by processing one step at a time in a series of actions.
RNN can learn from SMILES strings’ patterns and the molecules produced from the de
novo molecule procedure are chemistry-driven.
RNN combined with reinforcement learning was successfully employed in the de novo
drug design of novel molecular entities [88–90]. The first step of this method includes a
fine-tuned RNN that is pre-trained using existing bioactive molecules from a database such
as ChEMBL. Training of an RNN is generally performed through maximum likelihood
estimations of the next token in a target sequence of given tokens from the previous
steps [72]. Once the RNN has been trained on target sequences such as SMILES, it is
then used to generate new sequences that follow the conditional probability distributions
learned from the training set [72]. In the second step, a de novo drug-design agent is
generated based on a policy that maps a state to the probability of each action taken. Based
on a set of actions taken from states and the received rewards, the agent policy is improved
to increase the expected return. Two approaches have been used in reinforcement learning
to obtain a policy: policy-based RL in which a representation of the decision policy is
explicitly built and kept in memory during learning, or a value-based RL where only a
value function is stored while the policy is implicit. A task that has a clear endpoint is
referred to as an episodic task, which in the case of de novo drug design, is the generation
of a SMILES string for a novel molecular entity.
Several examples of DRL in de novo drug design that employed RNN were reported
in the literature, including a model that was trained to generate sulfur-free molecules using
augmented episodic likelihood [72]. Reinforcement Learning for Structural Evolution
(ReLeaSE) is an application of DRL to the problem of designing chemical libraries with
the desired physicochemical and biological properties [91]. This approach uses a special
type of stack-augmented RNN that was successful in inferring algorithmic patterns. This
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implementation considers SMILES strings as sentences composed of characters used in
SMILES notation. The objective of stack-RNN is to learn the hidden rules of forming
sequences of letters that correspond to legitimate SMILES strings. SMILES strings are used
for both generative and predictive phases of the method and these phases are integrated
into a single workflow. A fragment-based DRL approach, based on an actor-citric model,
for the automatic generation of molecules with improved properties, was developed
using RNN and RL [92]. This model learns how to modify molecules to improve their
properties by generating novel structures that are similar to existing bioactive compounds
of a given target. Thus, this approach does not attempt to search the entire chemical space
to find optimal candidate molecules; instead, it optimizes an existing lead compound by
adding fragments.
A multi-objective evolutionary de novo drug-design approach was developed using
RNN to generate novel molecules [93]. The best molecules were selected to retrain the
network using transfer learning (TL). In TL, a model is trained on a source task and then
retrained on a new related task called the target task [94]. TL has been proven to be efficient
in improving the accuracy of models based on narrowly defined tasks. A deep learning
methodology using a long short-term memory (LSTM) RNN was successfully employed in
de novo drug design [95]. The first part of this study involved training an LSTM-based
RNN model to generate libraries of valid SMILES strings with high accuracy. TL was then
used to fine-tune the model by generating molecules that are structurally similar to drugs
with known bioactivities against a particular biological target. This method was found to
be successful in the early stages of drug discovery where there is a low amount of data
available. The second part of this study involved the application of the generative model to
fragment-based drug discovery by growing a library of leads starting from a known active
fragment [95].
An interesting study demonstrated that molecular information, such as molecular
descriptors, can be incorporated into a conditional RNN generative process [96]. The
generation process of this approach was conditioned with properties calculated either
directly from molecular structures or QSAR, such that the encoder part was no longer
needed. The conditional seed successfully steered the focus of the RNN towards a particular
subset of the chemical domain, such as bioactive compounds of a biological target. A novel
way of assessing the focus of a probabilistic sequence generator was also achieved using
negative log-likelihood plots. An RNN trained on large sets of molecules was employed to
develop a data-driven de novo drug-design approach [89]. This study demonstrated that
an RNN trained on SMILES strings of molecules can both learn the grammar required to
generate valid SMILES and generate molecules with similar properties to the compounds
used for the training of the RNN [97]. A recent study assessed bidirectional molecule
generation with RNN, comparing three bidirectional strategies (novelty, chemical biological
relevance, and scaffold diversity) to the unidirectional forward RNN approach for the
computer-generated molecules with SMILES string generation [98].
5.2. Convolutional Neural Networks (CNN)
A convolutional neural network (CNN) is a type of artificial network consisting of
altering, convolution, and pooling layers, which enables them to extract features automati-
cally [99–101]. CNNs were extensively employed in image processing with great success
by running a small window over the input feature vector at both training and test phases
as a feature detector [77]. This process allows a CNN to learn various features of the input
regardless of their absolute position within the input feature vector [99]. DeepScaffold is a
comprehensive solution for scaffold-based de novo drug design that utilizes CNN and 2D
graphs of molecular structures [102]. This method can generate molecules based on a wide
spectrum of scaffold definitions including Bemis–Murcko scaffolds, cyclic skeletons, and
scaffolds with specifications of side-chain properties. An advantage of this method is its
ability to generalize the chemical rules of adding atoms and bonds to a given scaffold. The
compounds generated by DeepScaffold were evaluated by molecular docking to their asso-
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ciated biological targets, and the results suggested that this approach could be effectively
applied in drug discovery. DeepGraphMolGen is a multi-objective computational strategy
for generating molecules with desirable properties using a graph CNN and reinforcement
learning [103]. This strategy consists of property prediction and molecular generation in
which molecules were represented as 2D graphs, since they are a more natural molecular
representation than SMILES strings. Finally, a new framework for de novo drug design
was proposed based on a graph generation model. The graph generator was designed to be
suitable for the task of molecule generation using a simple decoding scheme and a graph
convolutional architecture that is less computationally expensive [104].
5.3. Generative Adversarial Networks (GAN)
A generative adversarial network (GAN) is a special type of neural network model
where two networks are trained simultaneously, with one focused on image generation
and the other centered on discrimination [105–107]. The generator typically captures
the distribution of true examples for new data example generation. The discriminator is
usually a binary classifier, discriminating the generated examples from the true examples
as accurately as possible. GANs have been found to be successful in image generation tasks,
including text-to-image synthesis, super-resolution, and image-to-image translation [105].
An original deep neural network (DNN) architecture called a reinforced adversarial neural
computer (RANC) was utilized for de novo drug design of novel small-molecule organic
structures based on a GAN and reinforcement learning [108]. RANC uses a differentiable
neural computer, a category of neural network with increased generation capabilities
due to the addition of an explicit memory bank mitigating common problems found in
adversarial settings, as the generator. RANC was able to generate structures that match the
distributions of key chemical descriptors and the lengths of SMILES strings in the training
dataset [108]. Adversarial threshold neural computer (ATNC) is another de novo drug-
design approach based on a GAN architecture and reinforcement learning. This approach
uses a differentiable neural computer as the generator and has a new specific block, called
an adversarial threshold, which acts as a filter between the agent (generator) and the
environment (discriminator and objective reward factions) [109]. To generate more diverse
molecules, a new objective reward function, named internal diversity, clustering (IDC)
was employed [109]. LatentGAN is a novel deep-learning architecture which combines
an autoencoder and a GAN for de novo drug design [110]. The utility of this method was
examined using two scenarios: the first to generate random drug-like compounds and the
second to generate target-biased compounds, with promising results in both cases. This
method generates molecules that differ from those obtained using RNN-based generative
models, indicating that these two approaches are complementary [110].
5.4. Autoencoders (AE)
5.4.1. Variational Autoencoder (VAE)
A variational autoencoder (VAE) is a stochastic variational inference and learning
algorithm that is extensively used to represent high-dimensional complex data via a
low-dimensional latent space learned in an unsupervised manner using encoders and
decoders [111]. De novo drug-design approaches using VAE include the development of a
method to convert discrete representations of molecules to a multidimensional continu-
ous representation [112]. In this study, a DNN was trained on hundreds of thousands of
existing chemical structures to construct three coupled functions: an encoder, a decoder,
and a predictor. The encoder converts the discrete representation of a molecule into a
real-valued continuous vector, and the decoder converts these continuous vectors back
into discrete molecular representations. The predictor estimates chemical properties from
the latent continuous vector representation of the molecules. This model allowed efficient
exploration of the chemical space through the development of optimized chemical struc-
tures. A shape-based generative approach for de novo drug design was developed using
CNN to generate novel molecules from a seed compound, its three-dimensional shape,
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and its pharmacophoric features [113]. A VAE is used to perturb the 3D representation
of a compound, followed by a system of convolutional and recurrent neural networks
that generate a sequence of SMILES tokens. The generative design of novel scaffolds
and functional groups performed by this method could cover unexplored regions of the
chemical space that still possess lead-like properties. A conditional VAE was employed
to develop a new molecular design strategy that directly produces molecules with the de-
sired target properties [114]. This method controls multiple target properties by imposing
them onto a condition vector. The authors demonstrated that it was possible to generate
drug-like molecules with specific values for the five target properties (molecular weight
(MW), octanol–water partition coefficient (LogP), number of hydrogen bond donors and
acceptors (HBD, HBA) and topological polar surface area (TPSA)) within an error range
of 10%. In addition, the authors were able to selectively control LogP without changing
the other molecular properties and to increase a specific property beyond the range of the
training set [114].
5.4.2. Sequence-to-Sequence Autoencoder (seq2seq AE)
A sequence-to-sequence autoencoder (seq2seq AE) is an artificial network architecture
that maps an input sequence to a fixed-sized vector in the latent space using a gated
recurrent unit (GRU) [115] or an LSTM network [116], and then maps the vector to a
target sequence with another GRU or LSTM network [117]. Thus, the latent vector is an
intermediate representation containing the “meaning” of the input sequence. In the case of
de novo drug design, the input and output sequences are both SMILES strings [118]. A
generative network complex was successful in generating new drug-like molecules based
on multi-property optimization via a gradient descent in the latent space of an autoen-
coder [118]. In this approach, both multiple chemical properties and similarity scores were
optimized to generate drug-like molecules with the desired properties. The predictions
of this method were validated using independent two-dimensional predictors based on
molecular fingerprints. Finally, the method was utilized to generate a large number of
new BACE1 inhibitors, as well as thousands of novel alternative drug candidates for eight
existing drugs currently on the market, including Ceritinib, Ribociclib, Acalabrutinib, Ide-
lalisib, Dabrafenib, Macimorelin, Enzalutamide, and Panobinostat [118]. A seq2seq AE was
also used to develop a de novo drug-design approach using SMILES strings [119]. Using
this method, the extent to which translation between different chemical representations
influences the latent space similarity to the SMILES strings or circular fingerprints was
explored. It was found that training a seq2seq hetero-encoder based on an RNN with LSTM
cells to predict different enumerated SMILES strings from the same canonical SMILES
string gives the largest similarity between latent space distance and molecular similarity
measured as circular fingerprints similarity [119].
5.4.3. Adversarial Autoencoder (AAE)
An adversarial autoencoder (AAE) is a probabilistic autoencoder that uses a GAN to
perform variational inference by matching the aggregated posterior of the hidden code
vector of an autoencoder with an arbitrary prior distribution [120]. An AAE that contains
both a generator and a discriminator was trained on a set of molecules with anti-tumor
growth activity [121]. The generated model was utilized to create molecules with the
desired properties in the form of fingerprints. A close examination of the newly generated
molecules showed that the newly created molecular fingerprints matched the structure
of highly effective anticancer drugs. An improvement in this architecture led to the
development of druGan, an AAE that incorporated additional molecular properties such as
solubility and allowed the generation of molecules with different chemical structures [122].
druGan showed better performance in terms of feature extraction, ability to generate
molecules, and reconstruction error compared to its predecessor AAE.
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6. Particle Swarm Optimization for De Novo Drug Design
Particle swarm optimization (PSO) is a stochastic optimization technique inspired
by swarm intelligence, which aims to find an optimal point in a search space defined
by an objective function. The particle swarm consists of individual agents (particles)
that optimize the given problem in parallel by making use of knowledge gained during
its search. Additionally, particles constantly exchange information about optimization
successes, and thus influence their direction of movement in the search space. During the
search, promising solutions are identified in the region that attracts most of the particles.
PSO has been successfully applied in the field of drug design for optimization of the
molecular properties of compounds with the desired biological properties. For example,
Hartenfeller et al. developed COLIBREE, an algorithm for fragment-based molecular de
novo drug design based on PSO optimization [123]. In their approach, PSO guides the
process of combinatorial de novo drug design. The constructed molecules follow a fixed
build-up scheme with three main elements: (1) a user-defined molecular scaffold, which is
used as the starting point for the molecular design; (2) building blocks which are molecular
fragments derived by pseudo-retrosynthesis from known bioactive molecules; (3) linkers
that represent substructures connecting two building blocks and link the building blocks to
the scaffold. The whole design process, including the selection of linkers, building blocks,
and structure assembly, is controlled by PSO, where each particle of the swarm identifies
new candidate compounds. These compounds are evaluated by a ligand similarity-based
fitness function to measure how far the new drug is from a reference set of drugs in a
topological atom-pair description space. The particles in the swarm gain knowledge during
the process, which is incorporated into the choice of new building blocks and linkers until
a final optimal solution is reached.
Winter et al. developed a computational methodology that integrates PSO with in
silico prediction of molecular properties such as biological activity and pharmacokinet-
ics [124]. They used a DNN to learn a compressed latent space representation of compounds
from 75 million chemicals. They defined a fitness function for the identification of the
best candidate drug as a combination of structure–activity-relationship knowledge (for
example, fixed ranges for molecular weight, and number of hydrogen-bonds.), a set of
targets that should be hit by the compound, and pharmacokinetics-related properties. The
PSO is used to search the compounds’ latent space and identify the optimal candidate
drug. The main advantage of this approach is that the optimization can be performed using
multiple objective functions simultaneously. However, the authors pointed out that this
methodology has to be used in combination with constraints to the part of the chemical
space that can be modeled within a reasonable applicability domain.
7. Evaluation Criteria
The design of new compounds is only the first step in the development of new drugs
and is followed by an iterative loop of synthesis, analysis, and molecular optimization.
However, not every generated compound can undergo this resource-intensive process.
Therefore, it is necessary to focus the efforts on a few promising de novo generated
compounds. For a compound to be relevant, it has to reach a balance between several
contrasting aspects, which include the right amount of novelty: it should not be too similar
to known drugs but also not too different so as to be completely unpredictable; it has to be
stable and synthesizable; it should be feasible to produce; and it should score highly in the
prediction of its desired properties (for example, target affinity and drug-likeness).
7.1. Diversity and Novelty
Generative models usually produce a population of chemical compounds on the order
of hundreds or thousands of generated samples. Of course, not every compound will be
unique; inevitably, some generated compounds will share characteristics to a lesser or
greater degree, and some others will be more similar to the training data, or the reference
database, depending on the specific method. It is especially important to test the capability
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of producing a wide variety of new structures when working with deep generative models,
as failure may happen where the generated samples lack variety (such as mode collapse
in GANs [125]) or the generated samples resemble the mean of the training distribution
too much (blurry samples produced by AE-based models). To explore the similarity of a
group of generated compounds against the reference set, several similarity scores have
been proposed depending on the representation format of the molecules. The edit (or
levenshtein) distance can be used to evaluate how different two SMILES strings are. If
the molecules are represented as substructure fingerprints, such as extended-connectivity
circular fingerprints (ECFP) or molecular access system (MACCS) keys, the Tanimoto and
Dice distances can be used. Finally, several graph similarity measures (or graph kernels)
have been proposed for evaluating the similarity of molecules represented by graphs, such
as the random walk kernel or the convolutional kernel [126].
Due to the novelty of these methods, standardized approaches do not yet exist when it
comes to specific workflows and validation guidelines for computer-assisted drug develop-
ment, such as, for example, the Organization for Economic Cooperation and Development
(OECD) rules for the validation of QSAR models [127]. Similarly, no guidelines cur-
rently exist on the acceptable ranges of evaluation metrics. This means that the selection
of good evaluation thresholds for new generated drugs is subjective, experiential, and
domain-specific and the decision is left to the human operator. As discussed in the next
session, a current workaround would be the application of well-established ADMET and
QSAR approaches, prior to synthesis and in vitro testing, for assessing the relevance of the
computer-designed molecules, as also stated by Muratov et al. [128]. In any case, further
work in this direction is required to identify specific criteria that computer-generated
compounds must fulfill, even if these are still subject to the same in vivo and in vitro tests
of a usual drug-discovery process.
7.2. Desired Properties
Virtually all the generative approaches rely on an evaluation mechanism that rewards
some aspects of the generated compounds, such as target affinity or desired bioactivity.
However, there are other “side” properties that, during the generating process, evolve
in a substantially unconstrained manner. Moreover, these side properties may represent
the difference between the success and failure of the development stages following the
design and synthesis of a candidate drug molecule. Examples of undesired side properties
include low drug-likeness scores [129] and undesired binding affinity with other complexes,
which may reduce the overall efficacy or even cause adverse effects and cellular toxicity.
Thus, in order to focus the synthesis efforts on the most promising generated compounds,
a prioritization mechanism is often employed. The easiest approach is filtering and/or
ranking of the generated molecules according to predicted drug-likeness, first introduced
by Lipinski et al. [45], or ADMET properties [130], such as the solubility of the molecule,
permeability of the brain–blood barrier, and affinity to transport proteins [126].
7.3. Synthetic Feasibility
Another concern is the actual capability of synthesizing the most promising de novo
generated compounds for further evaluation and optimization [6,18,22,131,132]. Left
unconstrained, generative models may propose overly complex or even impossible-to-
produce compounds. The generative process can be biased by penalizing the complexity of
the molecules, but at the expense of reduced efficacy [133]. Several evaluation functions
have been proposed to estimate the complexity of a generated compound, like the synthetic
accessibility (SA) score, which takes into account the presence of non-standard structural
features, such as large rings, non-standard ring fusions, stereocomplexity, and molecule
size [131], and the synthetic complexity (SC) score, which was trained using a reaction
corpus based on 12 million reactions from the Reaxys database to impose a pairwise
inequality constraint to ensure that reaction products are more synthetically complex than
their corresponding reactants [134]. In addition to filtering the results of the learning
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process, the ability to generate realistic compounds can also be enforced directly at the level
of the generation process. For example, the SPROUT algorithm assigns a different penalty
to each fragment while assembling the compounds based on a database of fragments
with known complexity [135]. The requirement of synthetic feasibility can be used as an
inductive bias while training a deep generative model to only design synthetically feasible
compounds. For example, MoleculeCHEF incorporates knowledge of basic reactants and a
chemical reaction prediction model, and generates molecules through a series of simulated
reactions [135]. Thus, each generated sample is expressed as a bag of base reactants
and a “recipe” of chemically stable reactions, which are supposed to produce the target
compound.
8. Bridging Toxicogenomics and Molecular Design
Toxicogenomics is the field of study that links the safety assessment of chemicals
to the underlying biological mechanisms [136,137]. One important aspect tackled by
toxicogenomics is the characterization of the mechanism-of-action (MOA) of a compound,
represented as the set of all molecular alterations induced by the exposure of an organism
(human) to it. Elucidation of the MOA allows understanding of the chain of biological
events (such as immune system activation, changes in the metabolism, and effects to the
cell cycle) triggered by a specific chemical (drug) exposure, which will lead to a phenotypic
endpoint (for example, toxicity). Merging the cheminformatic and toxicogenomic methods,
in combination with DL techniques, would facilitate and speed up the development of novel
approaches where chemicals are designed de novo to exert specific molecular alterations
and phenotypic effects.
Most of the approaches proposed to date are chemocentric, but new methodologies
that bridge toxicogenomics and molecular design are starting to emerge. For example,
Mendez-Lucio et al. developed a DL model based on a GAN whose training was condi-
tioned by gene expression data [138]. In a conditional generative model, target properties
for each compound are incorporated into the training and generative phases, in addition
to the compound chemical representation. Thus, conditional models learn a latent repre-
sentation space, which is a good representation of the compounds and of the conditional
variables. This makes the models useful both for reconstruction and predictive tasks. By
using this kind of approach, the trained model can be used to generate new compounds
with a predicted transcriptomic alteration similar to the one required in the input. This
approach, compared with more traditional similarity search-based approaches, has the
main advantage of not being limited to the initial pool of compounds for which the gene
expression signature is measured. Indeed, generative models can also help overcome
the limitation of the chemical space by generating new compounds tailored to match the
query gene expression signature. However, further work is required to assess the optimal
biological models in which to generate the gene expression signatures, especially in the
light of the variability of drug responses in cell lines, and the well-known limitations
(relative advantages and disadvantages) of utilizing cell lines versus primary cells.
9. De Novo Drug Design for COVID-19
The coronavirus SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic. The
novel nature of this virus urgently requires the development of efficient drug repositioning
and de novo drug-design approaches. The scientific community has been actively working
in this field and some of the well-known AI-based methods for drug design have been
applied to generate new compounds [139–141]. For example, Ton et al. developed a
novel DL platform, called deep docking, that provides fast prediction of docking scores
for structure-based virtual screening of billions of molecules simultaneously [142]. They
displayed their application by applying the deep docking method to more than one billion
compounds from the ZINC15 library and found 1000 potential ligands for the SARS-CoV-2
main protease (Mpro) protein. These candidate inhibitors are chemically diverse and have
superior docking scores compared to known protease inhibitors.
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Chenthamarakshan et al. have developed a new method, called CogMol, for target-
specific drug design for COVID-19 using deep generative models [143]. They first trained
a VAE to learn the SMILES representations of the molecules. Then, they used a pre-
trained protein sequence embedding from 24 million Uniprot protein sequences to train
a protein-molecule binding affinity regressor that they used to guide the generation of
new molecules. Finally, CogMol is empowered with an in silico screening protocol for the
generated molecules, which accounts for factors such as the toxicity prediction of a clinical
endpoint and the synthetic feasibility, and performs docking calculations to estimate the
binding of the generated molecules to target proteins. They used the CogMol framework
to generate candidate molecules to bind three relevant targets of the SARS-CoV-2 spike
protein with high affinity. From the generated drugs that passed the in vitro screening
filters less than 20 compounds, for each of the three protein targets considered, match an
existing SMILES in PubChem. Among them are Plasmepsin-2 and Plasmepsin-4 inhibitor,
ACE-2 inhibitors, and drugs approved for skin diseases and pneumonia. Since these drugs
have already been approved for specific uses, it should be faster to have them approved
for the treatment of COVID-19.
A different approach was applied by Tang et al. [144], who developed an advanced
deep Q-learning network with fragmented-based drug design for generating potential lead
compounds targeting the SARS-CoV-2 3C-like Mpro. Their approach starts from a molecular
fragment library built from a starting set of 284 molecules knowing to inhibit the SARS-
CoV-2 3C-like Mpro. Next, they applied an advanced deep Q-learning network, which
combines meaningful molecular fragments, for generating new candidate compounds.
They generated 4922 unique valid structures. Among these, 47 were selected by their
reward function (for example, how the agent “ought” to behave) and further evaluated
with docking and covalent docking studies [144].
Bai et al. developed a new tool for 3D drug design of protein targets, called Mo-
lAICal [145]. This tool combines deep generative models based on Wasserstein GAN
(WGAN) and virtual screening to generate new compounds starting from a library of
fragments from US FDA-approved drugs. They used MolAICal to generate new drugs
targeting the membrane protein glucagon receptor (GCGR) and the non-membrane protein
SARS-CoV-2 Mpro. They used 21,064 fragments of FDA-approved drugs extracted from the
e-Drug3D database and 1,060,000 drug-like ligands obtained from the ZINC database, and
showed that MolAICal can generate various ligands with high 3D structural similarity to
the crystal ligand of GCGR or SARS-CoV-2 Mpro.
10. Building Community and Regulatory Acceptance of DL Methods for De Novo
Drug Design
These COVID-19 examples demonstrate the power of DL methods for de novo drug
design and are likely to further accelerate the drug discovery pipeline and the repurposing
of existing drugs against alternative pathologies in the coming decade. However, since
the development of DL-based de novo drug design approaches is still at an early stage,
experimental validation of its effectiveness in drug discovery is crucial for the continuous
improvement of these methods and to support their widespread uptake into medicinal
chemistry practice and drug regulation. A recent report from the European Medicines
Agency (EMA) and Heads of Medical Agencies (HMA) on regulatory challenges from
big data suggested that “Algorithm code should be more transparent (feature selection,
code, original data set) and available for targeted review by regulators. Outcomes of,
and changes to, algorithm use (safety and efficacy) need to be subject to post-marketing
surveillance mechanisms, just like it is done today to monitor drug safety after marketing
authorization” [146]. A first key step is complete documentation of the DL models and the
underpinning datasets, as is the case, for example, for QSAR models, which are documented
using the QSAR model report format (QMRF), a harmonized template for summarizing
and reporting key information on QSAR models including the results of any validation
studies, structured according to the OECD QSAR validation principles. QMRFs are an
essential part of the validation and acceptance of QSARs for use in regulatory decision
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making, and thus, similar approaches for DL models would be an essential next step. While
the OECD have not yet developed specific guidance for DL models, they have published
a set of values-based principles for the development of AI methods [147] and position
papers on using AI to help combat COVID-19 [148], and on identifying and measuring
developments in AI [149].
Sharing of tools and approaches, via an open innovation model, is another essential
approach to achieving the promise of DL models for de novo drug design, as sharing the
training set and workflow can help with understanding the computational workflow and
gaining users’ trust. While this may not be entirely possible, due to privacy and policy
constraints, a workaround could be the release of a “training subset” that would allow
users to comprehend the model in question [150]. This can be achieved by constructing a
boundary tree, based on selected training data, which is able to closely approximate the
trained model. Traversing the datapoints in the tree can provide users with significantly
better understanding of the model and increased trust during model sharing [150]. While
some of the challenges for DL applications in medicine are related to patient data confiden-
tiality and the need for certainty where patient care options and treatment regimens are
being decided, many of the open innovation solutions currently being developed are likely
applicable. First efforts towards the establishment of a DL model sharing architecture and
marketplace have been demonstrated, to support the sharing of pretrained models across
different ML libraries and run-time environments, with a focus on model reusability, rather
than model development. In the future, standards or guidelines for model input/output
format definition, as well as data mapping rules and model validation procedures, will be
implemented [151].
11. Concluding Remarks
Since 1960, many forms of computer-aided drug design have generated a positive
impact in drug discovery. Among them, structure-based and ligand-based conventional
de novo drug design using evolutionary algorithms was employed for the development
of novel chemical entities. AI approaches including DRL have been successfully used
in the development of novel de novo drug-design approaches. Such methods include
DRL using artificial neural networks including recurrent neural networks, convolutional
neural networks, generative adversarial networks, and autoencoders. These methods are
also used in other computer-aided drug-design approaches and, based on the promising
acquired results, are expected to revolutionize the drug discovery and development pro-
cess, as well as to address some of the main challenges during the early stages of drug
discovery including cost and time demands, by developing in silico approaches for de novo
drug design, synthesis prediction, and bioactivity prediction. Indeed, as demonstrated
herein, the utility of DL-based de novo drug design for supporting drug repurposing
for COVID-19 treatment has been impressive and will likely accelerate adoption of the
approaches more broadly across the medical domain. The discovery of a new drug is
a complex, expensive, and time-consuming process. The traditional drug development
pipeline needs 12 years and 2.7 billion USD on average. The use of CADD algorithms and
tools could reduce drug development costs and time significantly with conservative esti-
mates suggesting AI pipelines require less than 1/3 of the current time and cost [152,153].
Examples of DRL-based de novo drug design include the development of adenosine A2A
receptor ligands [83], rapid identification of potent DDR1 kinase inhibitors [154], and the
development of a large number of new BACE1 inhibitors, which is an enzyme involved in
Alzheimer’s disease [118].
Standard de novo design methods rely on the interactions with the active site of a
biological target or the pharmacophores of a known active binder, and they are limited
by our partial understanding of receptor–ligand interactions. DRL-based de novo drug-
design approaches were developed with the goal of overcoming the limitations of existing
conventional approaches. These approaches are data-driven, flexible, versatile, and can
utilize a large amount of data from the scientific literature and databases. Besides the
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design of novel chemical entities, synthetic accessibility is also important in de novo
drug design. Conventional methods partially consider the synthetic feasibility of the
generated molecules based on a set of synthetic rules that are limited in a small number of
retrosynthetic organic reactions [22]. DL methods allowed the development of template-
free self-corrected retrosynthetic predictors to predict retrosynthesis using transformer
neural networks [155].
Although the development of DL approaches in drug discovery has just begun, there
is no doubt that the benefits are tremendous. However, there is still much to be done, since
recent property optimization studies are focused on easily optimizable properties, such as
drug-likeness [156], and efforts to integrate detailed understanding of modes of action and
toxicogenomics are only beginning. Key challenges remain in terms of building community
and regulatory acceptance of deep learning models, with documentation and sharing
of training datasets, development of standards for model validation and model-sharing
platforms as essential steps towards achieving this.
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Abbreviations
CADD Computer-aided drug design
QSAR Quantitative structure–activity relationships
NMR Nuclear magnetic resonance
DNDD De novo drug design
MCSS Multiple copy simultaneous search
ChEMBL Chemical database of bioactive molecules with drug-like properties




RNN Recurrent neural networks
CNN Convolutional neural networks
GAN Generative adversarial networks
AE Autoencoders
RL Reinforcement learning
DRL Deep reinforcement learning
SMILES Simplified molecular-input line-entry system
ReLeaSE Reinforcement learning for structural evolution
TL Transfer learning
LSTM Long short-term memory
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nll
2D Two-dimensional
DNN Deep neural network
RANC Reinforced adversarial neural computer
ATNC Adversarial threshold neural computer




LogP Octanol-water partition coefficient
HBD Hydrogen-bond donor
HBA Hydrogen-bond acceptor
TPSA Topological polar surface area
seq2seq AE Sequence to sequence autoencoder
GRU Gated recurrent unit
AAE Adversarial autoencoder
PSO Particle swarm optimization




COVID-19 Coronavirus disease 2019




US FDA United States food and drug administration
GCGR Glucagon receptor
EMA European medicines agency
HMA Heads of medical agencies
QMRF QSAR model report format
DDR1 Discoidin domain receptor 1
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